Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components

clipboard-pencil

About the study

This is a two-part, double-blind, placebo-controlled, randomized, multicenter Phase 2 clinical trial of JM-010 in patients with Parkinson's Disease.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

  1. Is able to read, understand, and provide written, dated informed consent prior to Screening Visit.
  2. Is male or female, between 18 and 85 years of age at Screening Visit.
  3. Is diagnosed with idiopathic PD that meets UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria
  4. Has experienced dyskinesia
  5. Has stable peak-effect dyskinesia
  6. Has more than one hour of "ON" time with troublesome dyskinesia

EXCLUSION CRITERIA

Exclusion Criteria:

  1. Has undergone surgery for the treatment of PD
  2. Has a current diagnosis of Substance Use
  3. Has psychiatric diagnosis of acute psychotic disorder or other psychiatric diagnoses
  4. Has current seizure disorders requiring treatment with anticonvulsants.

Other criteria related to other medical conditions to be referred to the protocol.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition
Dyskinesias,Parkinson Disease
Age (in years)
18 - 85
Phase
Phase 2
Participants needed
188
Est. Completion Date
Jul 17, 2024
Treatment type
Interventional

Sponsor
Bukwang Pharmaceutical
ClinicalTrials.gov identifier
NCT04377945
Study number
BK-JM-201

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.